Bottom line
BBH vs BIB: the short answer
BBH (VanEck Biotech ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 48% by weight.
But BIB is far broader, holding 267 positions to 25 for BBH, so beyond the top names it adds exposure BBH doesn't have.
BBH is cheaper at 0.35% vs 0.95% — a difference of $60 a year per $10,000 invested.
Over five years, BBH returned +2.7% a year vs −1.0% for BIB.
Updated Nov 19, 2026
BBH vs BIB side by side
| BBH | BIB | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | VanEck | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 0.95% |
| Annual cost per $10k | $35 | $95 |
| 10-yr cost on $10k (prospectus) | $443 | $1,401 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | +21.2% | +59.3% |
| 5-yr return (annualized) | +2.7% | −1.0% |
| 10-yr return (annualized) | +4.5% | +1.4% |
| Best quarter | +27.6% | +56.2% |
| Worst quarter | −18.2% | −42.7% |
| Net assets (fund) | $395.6M | $73.7M |
| Number of holdings | 25 | 267 |
| Portfolio turnover | 19% | 29% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BBH | BIB | Difference |
|---|---|---|---|
| 2025 | +21.2% | +59.3% | −38.2% |
| 2024 | −4.4% | −10.0% | +5.6% |
| 2023 | +3.9% | −1.3% | +5.1% |
| 2022 | −15.1% | −28.6% | +13.5% |
| 2021 | +11.8% | −5.9% | +17.7% |
| 2020 | +22.1% | +39.7% | −17.7% |
| 2019 | +25.8% | +45.5% | −19.8% |
| 2018 | −10.2% | −24.4% | +14.2% |
| 2017 | +16.6% | +40.8% | −24.1% |
| 2016 | −15.0% | −44.2% | +29.2% |
Source: Fund prospectus bar charts
Holdings overlap
13 of BBH's top 25 holdings also appear in BIB's top 25.
| Holding | BBH | BIB |
|---|---|---|
| Amgen Inc | 15.25% | 4.48% |
| Gilead Sciences Inc | 12.79% | 4.66% |
| Vertex Pharmaceuticals Inc | 9.10% | 4.65% |
| Regeneron Pharmaceuticals Inc | 6.21% | 3.21% |
| Revolution Medicines Inc | 5.27% | 1.57% |
| Argenx SE | 4.97% | 1.19% |
| Alnylam Pharmaceuticals Inc | 3.83% | 2.01% |
| Biogen Inc | 3.63% | 1.44% |
| Moderna Inc | 3.36% | 0.94% |
| Illumina Inc | 3.17% | 1.25% |
| United Therapeutics Corp | 2.83% | 1.22% |
| Insmed Inc | 2.67% | 1.16% |
| Incyte Corp | 2.49% | 0.97% |
Source: SEC Form N-PORT
BBH top 10
- Amgen Inc — 15.25%
- Gilead Sciences Inc — 12.79%
- Vertex Pharmaceuticals Inc — 9.10%
- Regeneron Pharmaceuticals Inc — 6.21%
- Revolution Medicines Inc — 5.27%
- Argenx SE — 4.97%
- Natera Inc — 4.92%
- IQVIA Holdings Inc — 4.31%
- Alnylam Pharmaceuticals Inc — 3.83%
- Biogen Inc — 3.63%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between BBH and BIB?
Which is cheaper, BBH or BIB?
Should I own both BBH and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.